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Clinical Application of the Urokinase-Immobilized 
Polyurethane Catheter 
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KAZUNOBU NISHIMURA, TOSHIHIKO BAN and KATSUHIKO SUYAMA 
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Urokinase-immobilized polyurethane tubes which had a thromboresistant luminal surface 
were used in 23 patients as central venous catheters. Cathetns were inserted into the inferior 
vena cava via the femoral vein at the time of operation to evaluate the central venous pressure 
and were then used for intravenous fluid therapy. These catheters were removed after one to 
10 days (average 4.8 days). Macroscopically, no thrombus was seen on the surface of the 
catheter. These catheters were examined by scanning electron microscopy to evaluate the 
surface characteristics. No thrombus formation was observed within five days. After seven 
days, the luminal surface of the catheter was covered with a thin cellular thrombus, formed by 
platelets, red blood cells and white blood cells entrapped in fibrin strands. Our study demon-
strated that the urokinase-immobilized catheter had adequate antithrombogenic actiYity for 
five days of clinical use. 
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内径（m×m外）径 素材 切断（k強g)力 切断（%伸）度初期（g／ヤmンmグ2）率 10；；ぢ伸（張g)時応力
I. 32×2. O (14 G) PU 10.1 863 5848 800 
EVA 4.4 850 ~047 300 
o.97×1.5 (16G) PU 6.2 1006 5093 500 






















































































CHD; congenital heart disease, !HD; ischemic heat disease, 
VHD; valvular heart disease 
Jレ酸緩衝液で洗浄し， 17ちオスミウム酸固定を行い，
























した．さらに5例（留置期間2' 4' 5' 7' 8日）
でカテー テJレ先端部分の表面性状を SEM（日立製 S
-450）を用いて観察し，対照としてポリ塩化ビニル
(PVC)カテー テノレ14G（外径 2mm）を使用した3例
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